CTEV vs TDOC

For growth investors, Claritev Corporation (CTEV) is the stronger pick with 3.

7% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Analysts rate Claritev Corporation (CTEV) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Claritev Corporation (CTEV) delivered a total return of +0.

8%, compared to -94. 8% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: CTEV returned +0. 8% versus TDOC's -37. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Teladoc Health, Inc.

(TDOC) is the lower-risk stock at 1. 82β versus Claritev Corporation's 2. 26β — meaning CTEV is approximately 24% more volatile than TDOC relative to the S&P 500.

By revenue growth (latest reported year), Claritev Corporation (CTEV) is pulling ahead at 3.

7% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Claritev Corporation grew EPS 83. 0% year-over-year, compared to 80. 6% for Teladoc Health, Inc.. Over a 3-year CAGR, TDOC leads at 1. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Teladoc Health, Inc.

(TDOC) is the more profitable company, earning -7. 9% net margin versus -29. 4% for Claritev Corporation — meaning it keeps -7. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTEV leads at 4. 7% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Teladoc Health, Inc.

(TDOC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Claritev Corporation (CTEV) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TDOC: -37. 7%, CTEV: +0. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.